The round, backed by Astellas and Celgene, will support development of Cleave's lead oncology drug candidate, and takes its total funding to $91m.

Johnson & Johnson led the series E round, which included Kaiser Permanente and Mayo Clinic, taking the medical device maker's total funding past the $100m mark.

Pfizer invested in Bamboo in the first quarter and has agreed to pay up to $645m in total to acquire the company, depending on milestones.

A round up of all the latest news on www.globalcorporateventuring.com for our subscribers.

General Electric has made its third investment in the blood flow monitoring technology developer, which has reportedly raised $75m since 2012.

Ambrx, which agreed an acquisition last year by a Fosun Pharma and WuXi PharmaTech-backed consortium, has secured funding from investors including Fosun, Sinopharm and Humanwell.

Roche's corporate venturing unit co-led the latest round to be closed by the healthcare analytics provider, which will be used for product development.

Healthkart, owned by Intel-backed Bright Lifecare, has added $12m to its coffers thanks to Sequoia Capital and Kae Capital.